EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

MIDD Evidence to Support Drug Regulatory Decisions in China

Lili Gao, Yan Wang, Ruirui He, Chunmin Wei

Clinical and Translational Science · 2026-07 · 19 (7)

DOI: 10.1111/cts.70656 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 10.07.2026. Verfasst von Lili Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation, National Medical Products Administration, China. Hauptthemen laut MEDLINE: Drug Development, Drug Approval. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The paper systematically reviews the technical guidelines for Model‐Informed Drug Development (MIDD) issued by China's Center for Drug Evaluation (CDE), analyzing typical application cases of innovative drugs approved both in China and internationally to evaluate MIDD's critical role in supporting drug development and regulatory decision‐making. As of December 2025, CDE has released seven specific guidelines focused on quantitative pharmacology models, covering the entire drug development lifecycle, including dose exploration and optimization, pediatric extrapolation, rare disease drug development, and exposure‐response (E‐R) relationship research. MIDD have been successfully applied across multiple domains in innovative drug development, optimizing dosing regimens through E‐R analysis for dose selection; constructing comprehensive evidence chains via modeling and simulation for pediatric and rare disease drug development; supporting dosage rationality through population PK andPBPK models for dose adjustments in special populations; and characterizing complex in vivo processes in advanced therapeutic products through mechanistic models. While MIDD enhances R&D efficiency and reduces clinical trial burdens, the field in China currently faces three major challenges: data quality, prospective design, and validation standards. It is necessary to strengthen data collection, model validation, and full lifecycle management to promote the paradigm shift from “model‐assisted” to “model‐driven” drug development, thereby accelerating the global market entry of Chinese innovative drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentDrug ApprovalHumansChinaModels, BiologicalGuidelines as Topic

Stichwörter der Autor:innen

ChinaMIDDinnovative drugs

Autor:innen und Institutionen

  • Center for Drug Evaluation, National Medical Products Administration, China.

Zitieren

APA

Gao, L., Wang, Y., He, R., & Wei, C. (2026). MIDD Evidence to Support Drug Regulatory Decisions in China. Clinical and Translational Science, 19(7). https://doi.org/10.1111/cts.70656

Vancouver

Gao L, Wang Y, He R, Wei C. MIDD Evidence to Support Drug Regulatory Decisions in China. Clinical and Translational Science. 2026;19(7). doi:10.1111/cts.70656

BibTeX
@article{Gao2026,
  author = {Gao, Lili and Wang, Yan and He, Ruirui and Wei, Chunmin},
  title = {MIDD Evidence to Support Drug Regulatory Decisions in China},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {7},
  doi = {10.1111/cts.70656}
}
Kostenlos starten →